Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current trends in screening across ethnicities for hypersensitivity to abacavir.

Pharmacogenomics - 1 Oct 2008

Rodriguez-Nóvoa Sonia, Soriano Vincent

Abstract excerpt

Abacavir is a potent nucleoside analog reverse transcriptase inhibitor approved for the treatment of HIV infection. Approximately 5-8% of Caucasian patients receiving abacavir develop a hypersensitivity reaction, characterized by rash, fever and, occasionally, multisystemic involvement. Rechallenge with the drug can be fatal. The discovery of the mechanisms involved in this hypersensitivity reaction and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Dideoxynucleosides
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forecasting

Share to HLA-B Antigens

Share to Models, Immunological

Share to Reverse Transcriptase Inhibitors

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 18855539
DOI: 10.2217/14622416.9.10.1531

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current trends in screening across ethnicities for hypersensitivity to abacavir.PMID 18855539Read ↗

HLA-B*5701 testing to predict abacavir hypersensitivitySemantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.Semantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.Semantic proximity Read ↗

[HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicineSemantic proximity Read ↗

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.Semantic proximity Read ↗

[HLA-B*5701 and abacavir hypersensitivity reaction].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.